Related Experiment Video
Updated: Aug 5, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Clinical Guidance on the Safe Use of Sodium-Glucose Cotransporter Inhibitors in Adults with Type 1 Diabetes
Jayachidambaram Ambalavanan1, Kanchan Bhasin2, Viral N Shah2
1Division of Endocrinology, Diabetes and Metabolism, Maine Health Maine Medical Center and Tufts University School of Medicine, Scarborough, ME, USA.
Abstract:
Sodium-glucose cotransporter inhibitors (SGLTi) as an adjunctive to insulin therapy may offer cardiometabolic and renal benefits in adults with type 1 diabetes (T1D). Their effective use depends on patient selection, education, and ketone monitoring to prevent diabetic ketoacidosis (DKA). Starting with the lowest effective dose, making appropriate insulin adjustments, and following structured protocols for ketone monitoring and DKA risk mitigation are essential for safe use of SGLTi in adults with T1D.
Related Concept Videos
Hypoglycemia and Glucagon
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes: Symptoms, Diagnosis, and Complications
Oral Hypoglycemic Agents: Glinides